Ad-hoc News
30.09.2009
biolitec AG achieved consolidated sales of Euro 30.5 million for the fiscal year 2008/2009 – EBIT amounts to Euro 0.31 million
Jena, September 30, 2009 – biolitec AG, Jena, listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409), generated consolidated sales of 30.5 million for the fiscal year 2008/2009 (previous year: Euro 35.4 million). The decrease in turnover in particular is due to the current economic crisis in the USA and Europe. The unfavorable investment climate worldwide, the low US dollar exchange rate and the reticence of the economic operators fearing an ongoing recession have decreased sales in 2008/2009 by about 14 percent compared to the previous year.
The gross profit amounted to Euro 21.4 million (previous year: Euro 23.9 million) and the EBIT Euro 0.31 million. R&D expenditures amounting to Euro 3.2 million in the fiscal year 2008/2009 (14 percent of the sales) remained on a high level, but have been reduced by Euro 1.84 million compared to the previous year. In the development and market launch of new products significant progress has been achieved. Due to the initiated restructuring measures, in this fiscal year a net income of Euro 0.64 million (previous year: Euro 1.98 million) could be generated despite the still high R&D expenditures and the decline in sales. Liquid assets are over Euro 6 million at the end of the fiscal year.
The sector optical fibers/ laser probes in 2008/2009 with over Euro 20 million remained around the previous year’s level with only slight losses (-5 percent). The turnover of the laser segment with Euro 8 million was significantly lower than in the previous year, primarily because of the recession in the US markets and Europe. In the pharma sector biolitec could register an increase in turnover by 21 percent up to Euro 1.7 million. Main roles in generating turnover still play the treatments of the benign prostatic hyperplasia (BPH) LIFE™ and the endoluminal treatment of veins (ELVeS™).
The essential turnovers of biolitec have been generated in Europe and North America. The turnover in North America amounted to Euro 11 million and so was significantly lower than in the previous year. Sales in Europe were Euro 15.5 million (previous year: 17.9 million). In Asia / Rest of the World, biolitec could significantly increase turnover by 43 percent. In South America and the Middle East, affiliates founded in 2008 already are profitable and contribute to turnover.
biolitec expects sales growth to resume for this fiscal year.
